Johnson & Johnson (JNJ) - Stock Report

The latest proof is mixed but not broken. In the fiscal first quarter ended 29 March 2026, worldwide sales were $24.1 bn, up 9.9% reported and 6.4% operational; Innovative Medicine delivered $15.4 bn of sales, up 11.2% reported and 7.4% operational, while MedTech delivered $8.6 bn, up 7.7% reported and 4.6% operational. The pressure point is still visible: STELARA biosimilar erosion reduced worldwide operational sales by about 5.4%, even as oncology growth, CAPLYTA, TREMFYA momentum and cardiovascular devices helped offset the drag. Cash and marketable securities were $22.1 bn against $55.0 bn of debt, so the dividend remains supported by a large cash engine, but net debt and litigation liabilities make cash conversion the key metric.

The key macro issue is not healthcare defensiveness in isolation, but whether patent-cliff and net-pricing pressure can be absorbed through new-product sales, segment margin and post-capex cash flow: if JNJ's replacement portfolio carries the mix, the balance sheet can keep funding dividends and pipeline investment; if erosion outruns replacement, the same payout profile becomes a tighter claim on cash.

Johnson & Johnson is now a two-segment healthcare company after the Kenvue separation. Innovative Medicine develops and commercializes branded therapies across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease and cardiovascular/metabolism. MedTech sells devices and systems used in cardiovascular intervention, surgery, orthopaedics and vision care.

The value stack is not simply "pharma plus devices." Innovative Medicine supplies the high-margin intellectual-property economics: clinical evidence, market access, physician adoption, patent life and lifecycle management convert R&D into premium-priced products. MedTech supplies procedural durability: installed clinical relationships, surgeon training, device iteration and hospital purchasing channels create recurring demand tied to procedure volumes. The combined model is valuable when high-margin drug cash flow funds both pipeline renewal and device reinvestment without letting patent cliffs or acquisitions absorb the owner's surplus.

The portfolio is mixed by modality. JNJ owns biologics and cell therapies that face biosimilars or complex competitive entry, but it also owns small-molecule products where generic or IRA pricing pressure can be faster and more direct. That distinction matters because the replacement cycle is different for DARZALEX, STELARA, TREMFYA, XARELTO, ERLEADA, OPSUMIT and CAPLYTA.